Skip to content
Open access

Single-Atom Modification Enables Reversal of Degradation Selectivity between NSD2 and GSPT1

Sep 2026 · bioRxiv · 0 citations · 23 references
Biology

TL;DR

These findings demonstrate that minimal structural alteration permits precision control over degrader target selectivity, while furnishing selective chemical probes for NSD2 and GSPT1.

Abstract

Both NSD2 and GSPT1 represent compelling targets for anti-cancer drug discovery. Herein, we carried out single-atom modification of LLC0424, an NSD2 degrader with GSPT1 neosubstrate engagement, to yield two structurally analogous molecules with divergent modes of action: 424-ND, an NSD2-selective degrader, and 424-GD, a GSPT1-selective degrader. 424-ND drove selective NSD2 degradation and suppressed androgen receptor (AR) signaling in prostate cancer cells. 424-GD induced selective degradation of GSPT1 and upregulated the integrated stress response markers ATF4 and ATF3. Biolayer interferometry revealed distinct ternary complex cooperativity profiles in the presence of NSD2 or GSPT1, which directly correlate with the observed biased degradation activity. Molecular dynamics and metadynamics simulations showed that the compounds adopt distinct low-energy conformational ensembles with different spatial orientations, likely underlying their divergent cooperativity and selectivity. These findings demonstrate that minimal structural alteration permits precision control over degrader target selectivity, while furnishing selective chemical probes for NSD2 and GSPT1.

Read PDF

Similar papers

Oct 2026

Design, synthesis, and anti-AML activity of Hyt-based LSD1 degraders.

Lysine-specific demethylase 1 (LSD1, KDM1A) drives oncogenic progression in acute myeloid leukemia (AML) through both catalytic histone demethylation and non-catalytic scaffolding interactions with oncogenic transcription factors. Conventional LSD1 inhibitors either suffer from severe off-target toxicity or fail to blo...

Yan-Le Zhi, Yi-Ping Gu, Jia-Hao Guo et al. · 0 citations
Sep 2026

A 2-in-1 Strategy for the Discovery of Compact HDAC8 Protac Degraders

A “2-in-1” PROTAC design strategy for developing more compact HDAC8 degraders by integrating the CRBN-recruiting ligand into the capping group of an HDAC8 warhead, thereby enabling a single structural motif to engage both HDAC8 and CRBN.

Yi Liu, Nikee Awasthee, Yufeng Xiao et al. · 0 citations
#protein folding Open access Oct 2026

Selective PTP1B inhibition by A-1331852: Uncompetitive kinetics and computational evidence for C-terminal engagement.

Repurposing the clinical-stage Bcl-xL BH3 mimetic A-1331852 is identified as a potent PTP1B inhibitor demonstrating a selectivity margin of at least 50-fold over TCPTP, highlighting A-1331852 as a promising starting point for developing PTP1B inhibitors designed to exploit transient, substrate-induced binding states.

Nathaly Vasquez-Martínez, Alejandro Sosa-Peinado, Francisco Cortés-Benítez et al. · 0 citations
Sep 2026

Targeting the “Undruggable” STAT3 DBD: Free-Energy Perturbation-Guided Design of Covalent Micheliolide Derivatives Targeting Cysteine 367

This study establishes C367 as a druggable covalent site in the historically challenging STAT3 DBD, validates FEP-guided optimization of covalent inhibitors, and identifies compound 16 as a promising next-generation lead with a superior drug-like profile for targeting STAT3-dependent cancers.

Yang-Ping Deng, H. Bian, Feng-Yuan Zhang et al. · 0 citations
#protein folding Open access Sep 2026

Dual-Site Covalent Targeting Enables BD2-Selective BET Inhibition With Potent Antitumor Activity in Mice.

Bromodomain and extra-terminal (BET) proteins are validated therapeutic targets for cancer, but clinical translation of pan-BET inhibitors is limited by dose-limiting toxicities from non-selective inhibition of BD1/BD2 domains. Herein, we report the first-ever domain-selective covalent inhibitor, named ipAE1, of BET BD...

Ji-Bo Kang, Xuan Wang, Hong Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.